Figure 2.
The mechanism of PRP in ONFH treatment. PRP: platelet-rich plasma; PDGF: platelet-derived growth factor; TGF-β: transforming growth factor-β; bFGF: basic fibroblast growth factor; EGF: endothelial growth factor; IGF: insulin-like growth factor; VEGF: vascular endothelial growth factor; IL-17A: interleukin-17A; IL-lβ: interleukin-1β; IL-6: interleukin-6; TNF-α: tumor necrosis factor-α; RANKL: receptor activator of nuclear factor-κ B ligand; Akt: protein kinase B; Bad: Bcl-2-associated death promoter; Bcl-2: B-cell lymphoma 2.